V Hess

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial
    Viviane Hess
    University Hospitals of Basel, Switzerland
    J Clin Oncol 21:66-8. 2003
  2. ncbi CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
    Viviane Hess
    Division of Medical Oncology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
    Lancet Oncol 9:132-8. 2008
  3. ncbi [Adjuvant!Online--an Internet-based decision tool for adjuvant chemotherapy in early breast cancer]
    Viviane Hess
    Medizinische Onkologie, Universitatsspital Basel, Petersgraben 4, Basel
    Ther Umsch 65:201-5. 2008
  4. ncbi [Surveillance after primary resection of esophageal, gastric, pancreatic, hepatobiliary cancer and gastrointestinal stroma tumor (GIST)]
    Viviane Hess
    Medizinische Onkologie, Universitatsspital Basel, CH 4031 Basel
    Ther Umsch 65:347-51. 2008
  5. ncbi Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial
    V Hess
    Department of Medical Oncology, University Hospital Zurich, Switzerland
    Ann Oncol 21:2390-5. 2010
  6. ncbi Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer
    D Koeberle
    Division Oncology Hematology, Department of Internal Medicine, Kantonsspital St Gallen, St Gallen CH 9007, Switzerland
    Br J Cancer 98:1204-9. 2008
  7. ncbi Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK
    Ute Gick
    Department of Medical Oncology, University Hospital Inselspital, Bern, Switzerland
    Oncology 71:54-60. 2006
  8. ncbi Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting
    Viviane Hess
    Department of Medical Oncology, University Hospital Basel, Basel, Switzerland
    Oncology 73:33-40. 2007
  9. ncbi Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment
    Viviane Hess
    Gynecology Unit, Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, UK
    J Clin Oncol 22:1040-4. 2004

Collaborators

Detail Information

Publications9

  1. ncbi Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial
    Viviane Hess
    University Hospitals of Basel, Switzerland
    J Clin Oncol 21:66-8. 2003
    ..CONCLUSION: The combination of capecitabine and gemcitabine is well tolerated, with apparent efficacy in patients with APC. Therefore, it is currently being compared with gemcitabine monotherapy in a phase III study...
  2. ncbi CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
    Viviane Hess
    Division of Medical Oncology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
    Lancet Oncol 9:132-8. 2008
    ....
  3. ncbi [Adjuvant!Online--an Internet-based decision tool for adjuvant chemotherapy in early breast cancer]
    Viviane Hess
    Medizinische Onkologie, Universitatsspital Basel, Petersgraben 4, Basel
    Ther Umsch 65:201-5. 2008
    ..This article focuses on the advantages and pitfalls in using Adjuvant!Online for informed treatment decisions in early breast cancer...
  4. ncbi [Surveillance after primary resection of esophageal, gastric, pancreatic, hepatobiliary cancer and gastrointestinal stroma tumor (GIST)]
    Viviane Hess
    Medizinische Onkologie, Universitatsspital Basel, CH 4031 Basel
    Ther Umsch 65:347-51. 2008
    ..This manuscript gives some practical guidance on how to individually follow these patients after primary tumor resection...
  5. ncbi Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial
    V Hess
    Department of Medical Oncology, University Hospital Zurich, Switzerland
    Ann Oncol 21:2390-5. 2010
    ..The purpose of this study was to determine dose, safety and preliminary efficacy of a first-line regimen combining all three classes of active cytotoxic drugs in APC...
  6. ncbi Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer
    D Koeberle
    Division Oncology Hematology, Department of Internal Medicine, Kantonsspital St Gallen, St Gallen CH 9007, Switzerland
    Br J Cancer 98:1204-9. 2008
    ..Preoperative capecitabine, oxaliplatin and RT achieved encouraging rates of pCR, R0 resection, sphincter preservation and tumour downstaging in patients with locally advanced rectal cancer...
  7. ncbi Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK
    Ute Gick
    Department of Medical Oncology, University Hospital Inselspital, Bern, Switzerland
    Oncology 71:54-60. 2006
    ..However, based on the efficacy data alternative schedules deserve further evaluation...
  8. ncbi Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting
    Viviane Hess
    Department of Medical Oncology, University Hospital Basel, Basel, Switzerland
    Oncology 73:33-40. 2007
    ..The role of Interleukin-2 (IL-2)-based biochemotherapy (BCT) for patients with metastatic melanoma remains controversial and few data of patients treated outside a specialized trial setting are available...
  9. ncbi Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment
    Viviane Hess
    Gynecology Unit, Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, UK
    J Clin Oncol 22:1040-4. 2004
    ..Specific alternative therapeutic approaches should be sought for this group of patients, perhaps involving fluorouracil-based chemotherapy...